Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity
Cisplatin is a widely used drug in the treatment of various solid tumors, such as ovarian cancer. However, while the acquired resistance significantly limits the success of therapy, some tumors, such as colorectal cancer, are intrinsically insensitive to cisplatin. Only a small amount of intracellul...
Main Authors: | Sophie Möltgen, Eleonora Piumatti, Giuseppe M. Massafra, Sabine Metzger, Ulrich Jaehde, Ganna V. Kalayda |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/6/1322 |
Similar Items
-
Changes in endogenous tissue glutathione level in relation to murine ascites tumor growth and the anticancer activity of cisplatin
by: Khynriam D., et al.
Published: (2003-01-01) -
Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
by: Juan Pablo Cayún Pellizaris, et al.
Published: (2014-11-01) -
EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin through autophagic pathway in human colorectal cancer cells
by: Fen Hu, et al.
Published: (2015-05-01) -
Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer
by: W.J. Sheng, et al.
Published: (2013-08-01) -
ROLE OF TRANSPORTERS IN THE DISTRIBUTION OF PLATINUM-BASED DRUGS
by: Saliha eHarrach, et al.
Published: (2015-04-01)